3D Medicines Corporation (3DMed), a precision cancer care medicine specialist, has raised $140 million in its debut funding round after spinning off its affiliate 3D Diagnosis into an independent company in 2018, per its announcement on Friday.
Register now to enjoy 3 free articles per month,
or log in to continue reading.
Stay informed with complimentary articles each month
Gain access to our exclusive newsletters delivered directly to your inbox
Be the first to know about all our summits!
Already a Subscriber? Log in
